You are here

Coronary Intervention & Surgery

 

A cross-sectional study of nearly 1,300 patients revealed Chinese physicians systematically overestimate the severity of coronary stenosis, perhaps even more so than in the United States, likely leading to many patients being inappropriately treated with percutaneous coronary intervention (PCI).

The risk of another heart attack following percutaneous coronary intervention (PCI) was twice as likely to originate from a previously untreated lesion versus the stented lesion, according to a study of a large Swedish cohort published in the Journal of the American Heart Association.

Patients are significantly more likely to die within one year of coronary artery bypass graft (CABG) surgery or PCI in New York state than in England where the procedures are roughly four times cheaper, according to a study in Open Heart.

Temporarily cooling part of the heart during myocardial infarction (MI) and again immediately after angioplasty may reduce damage to the heart, said a cardiologist who participated in the first in-human study of the technique.

Charles E. Chambers, MD, spoke with Cardiovascular Business about the risks of radiation exposure to interventional cardiologists and potential solutions.

 

Recent Headlines

Patients with degenerative mitral valve disease see better results with experienced surgeons

A database analysis in New York found that the mitral valve case volume of individual surgeons had a significant impact on patient outcomes following surgery.

Communication, coordination among hospital leaders and physicians improve surgical outcomes

In October 2010, some hospitals in South Carolina began implementing a customized surgical safety checklist patterned after a checklist that the World Health Organization developed. Hospitals implemented the 12-step process that focused on teamwork, training and monitoring progress.

SCAI announces late-breaking clinical trials sessions

The Society for Cardiovascular Angiography and Interventions (SCAI) recently announced the late-breaking clinical trials sessions for the SCAI 2017 scientific sessions.

FDA approves Medtronic’s Resolute Onyx drug-eluting stent

The U.S. Food and Drug Administration (FDA) approved the Resolute Onyx drug-eluting stent for adults with coronary artery disease.

Risk score may help predict mortality in cardiogenic shock patients

Researchers in Germany have developed a risk prediction score that strongly correlated with mortality in patients who suffer from cardiogenic shock following an acute MI.

Cardiologist treats first patient in study evaluating orbital atherectomy system

Cardiovascular Systems recently announced the first patient had enrolled in the company’s ECLIPSE trial, which is evaluating its Diamondback 360 coronary orbital atherectomy system.

AATS releases guidelines on concomitant surgical ablation in AFib patients

Patients with atrial fibrillation (AFib) who undergo concomitant surgical ablation have an improvement in 30-day operative mortality, long-term survival and health-related quality of life, according to new expert consensus guidelines from the American Association for Thoracic Surgery (AATS).

Hospitals using surgical safety checklists have 22 percent lower 30-day mortality rates

Hospitals in South Carolina that completed a voluntary, team-based surgical safety checklist had a significantly lower rate of 30-day post-operative mortality compared with hospitals that did not complete the program by the end of 2013, according to a population-based study.

Most patients with cardiovascular disease do not see a provider before having a STEMI

Fewer than half of patients with cardiovascular disease saw a primary care provider and fewer than 40 percent saw a cardiovascular provider during the two years before they had a ST-segment elevation MI (STEMI), according to a prospective cohort study.

PinnacleHealth to test efficacy of stroke reduction TAVR tool

In a new clinical trial at PinnacleHealth, based in Harrisburg, Pennsylvania, researchers are testing the efficacy of the Keystone Heart TriGuard, a device designed to reduce the risk of stroke during transcatheter aortic valve replacement (TAVR) procedures.

Pages